The net revenue is reported at Rs 129.41 crore
Lincoln Pharmaceuticals has reported a net profit of Rs 22.88 crore for the Q2 FY22 ended September 2021 as against a net profit of Rs 20.20 crore in the corresponding period last year, a growth of 13.27 per cent. The net revenue for the quarter was reported at Rs 129.41 crore, higher by 4.78 per cent over the previous fiscal’s same period net revenue of Rs 123.51 crore. EBITDA for the quarter was reported at Rs 31.95 crore as compared to Rs 29.02 crore in the corresponding period last year. EPS was reported at Rs 11.44 per share for Q2FY22 as compared to Rs 10.10 per share in the corresponding period last year.
Mahendra Patel, MD, Lincoln Pharmaceuticals said, “The company has delivered a robust operational and financial performance during the quarter and is confident to improve our growth numbers going forward. Recently the company has also received approval from Australia’s medicines and medical devices regulator – Therapeutic Goods Administration (TGA) for its Khatraj facility. TGA and EU GMP approvals will further strengthen the company’s presence in the export market. Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term.”
